Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy
Camillo Porta(University of Pavia), Mei Sheng Duh(Analysis Group (United States)), Chiara Paglino, Maureen P. Neary(GlaxoSmithKline (United States)), Kristina Chen(Takeda (United States)), Ilaria Imarisio(University of Pavia), Cinzia Canipari(University of Pavia)
Cited by 36
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|275